| Dataset | Model | Events in etanercept group | Events in control group | HR (95% CI) | p Value |
| Full | Fixed effects survival model stratified by trial | 26 | 7 | 1.84 (0.79 to 4.28) | 0.16 |
| Full | Random effects survival model stratified by trial | 26 | 7 | 1.82 (0.78 to 4.22) | 0.17 |
| NMSC excluded | Fixed effects survival model stratified by trial | 17 | 4 | 1.86 (0.62 to 5.59) | 0.27 |
| Cancers diagnosed within first 42 days excluded | Fixed effects survival model stratified by trial | 23 | 6 | 1.87 (0.75 to 4.62) | 0.18 |
| <6 Months | Fixed effects survival model stratified by trial | 8 | 3 | 1.52 (0.35 to 6.55) | 0.99 |
| 6–12 Months | Fixed effects survival model stratified by trial | 12 | 1 | 5.81 (0.73 to 46.16) | 0.17 |
| >12 Months | Fixed effects survival model stratified by trial | 6 | 3 | 0.88 (0.21 to 3.66) | 0.86 |
| Full | Fixed effects survival model, treatment varying with ln(time) | 26 | 7 | 0.97 (0.47 to 2.01) | 0.93 |
| Aggregate data | Fixed effects Mantel–Haenszel model | 26 | 7 | 1.93 (0.85 to 4.38) | 0.12 |
| Aggregate data | Random effects DerSimonian and Laird model | 26 | 7 | 1.71 (0.73 to 4.01) | 0.21 |
HR, hazard ratio; NMSC, non-melanoma skin cancer.